文献速递耳科与耳神经

前庭与平衡障碍主诉患者中多重用药的患病率

Prevalence of Polypharmacy in Patients With Vestibular and Balance Complaints.
PubMed 文献 · Ear Hear · 2022-11-15

该回顾性横断面研究纳入2019年9月1日至2020年3月31日以头晕为主诉就诊于三级神经耳科门诊的382例新患者,发现69.4%符合多重用药标准(≥5种药物),其中94.0%使用潜在耳毒性药物,约10%存在耳毒性多重用药;多重用药与年龄、糖尿病、高血压、其他心血管共病、抑郁、轻至中度听力损失及中至重度DHI评分相关,且CFQ评分更高。

要点

  • 382例头晕患者中69.4%符合多重用药(≥5种药物),94.0%使用潜在耳毒性药物。
  • 约10%患者使用≥5种耳毒性药物(耳毒性多重用药)。
  • 多重用药与糖尿病、高血压、心血管共病、抑郁及轻中度听力损失相关。

核心结论

  • 前庭障碍患者中多重用药患病率高,部分药物具有不同程度潜在耳毒性。
  • 多重用药与患者报告结局指标(DHI、CFQ)评分较差似乎相关。
  • 作者认为药物核对和多学科参与可能有助于更好地处理该患者人群的多重用药。
  • 原文指出需进一步研究以阐明多重用药在症状表现、前庭检查结果和治疗策略中的作用。

研究设计与样本

  • 回顾性横断面综述,纳入2019年9月1日至2020年3月31日以头晕为主诉就诊于三级神经耳科门诊的新患者382例。
  • 从病历中提取人口学、症状、诊断、药物、听力检查、头晕残障指数(DHI)和认知失败问卷(CFQ)评分。

主要发现

  • 382例患者中265例(69.4%)符合多重用药标准(≥5种药物),其中249例(94.0%)使用潜在耳毒性药物。
  • 约10%患者使用≥5种耳毒性药物(耳毒性多重用药)。
  • 多重用药与年龄相关,且在糖尿病、高血压、其他心血管共病和抑郁患者中更常见(OR 3.73-6.67;p<0.05)。
  • 轻度和中度听力损失患者多重用药可能性约为两倍(OR 2.02 [1.24-3.29]和OR 2.13 [1.06-4.27];p<0.05),中度和重度DHI评分患者多重用药可能性约1.5倍(OR 1.65 [1.05-2.59]和OR 1.63 [1.00-2.65];p<0.05)。
  • 多重用药患者CFQ评分高于无多重用药患者(CFQ 32.5 [19.0-48.0] vs CFQ 25.0 [13.0-40.0];p=0.002);以头重脚轻为头晕描述的患者耳毒性多重用药更常见(OR 3.16 [1.56-6.41];p<0.01),耳毒性多重用药仅在轻度和中度听力损失(OR 2.69 [1.33-5.45]和OR 2.86 [1.31-6.20];p<0.01)及重度DHI评分(OR 2.31 [1.12-4.77];p=0.02)患者中更常见。

临床怎么用

  • 作者认为药物核对和多学科参与可能有助于更好地处理该患者人群的多重用药。
  • 原文未据此给出其他推荐。

局限性

  • 原文指出需进一步研究以阐明多重用药在症状表现、前庭检查结果和治疗策略中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the prevalence of polypharmacy in patients presenting with dizziness to a tertiary neurotology clinic and analyze the association between polypharmacy and clinical characteristics. DESIGN: Retrospective, cross-sectional review. Demographics, symptoms, diagnoses, medications, audiometry, dizziness handicap index (DHI) scores, and cognitive failure questionnaire (CFQ) scores were extracted from charts of patients seen as new patients from September 1, 2019, to March 31, 2020, with a primary complaint of dizziness. RESULTS: A total of 382 patients were included. More than two-thirds of the patients (n = 265, 69.4%) met criteria for polypharmacy (≥5 medications), of which most (n = 249, 94.0%) were prescribed a potentially ototoxic drug. Approximately 10% of patients were taking five or more ototoxic medications (oto-polypharmacy). Polypharmacy was correlated to age and was more common for patients with diabetes, hypertension, other cardiovascular comorbidities, and depression (odds ratio [OR], 3.73-6.67; p < 0.05). Polypharmacy was twice as likely in patients with mild to moderate hearing loss (OR 2.02 [1.24-3.29] and OR 2.13 [1.06-4.27], respectively; p < 0.05) and ~1.5× more likely in patients who had moderate to severe DHI scores (OR 1.65 [1.05-2.59] and OR 1.63 [1.00-2.65], respectively; p < 0.05). Patients with polypharmacy also had higher CFQ scores compared to those without polypharmacy (CFQ 32.5 [19.0-48.0] versus CFQ 25.0 [13.0-40.0]; p = 0.002. Oto-polypharmacy was more common for patients with lightheadedness as a dizziness descriptor (OR 3.16 [1.56-6.41]; p < 0.01). However, oto-polypharmacy was only more common for patients with mild to moderate hearing loss (OR 2.69 [1.33-5.45] and OR 2.86 [1.31-6.20], respectively; p < 0.01) and severe DHI scores (2.31 [1.12-4.77], p = 0.02). CONCLUSIONS: The prevalence of polypharmacy in patients with vestibular disorders is high. Some of the medications that patients are on are also potentially ototoxic at variable degrees. Polypharmacy is more common when lightheadedness is one of the dizziness descriptors and seems to be associated with worse scores on patient-reported outcome measures (DHI, CFQ). Medication reconciliation and multidisciplinary involvement could help to better address polypharmacy in this patient population. However, further investigation is needed to elucidate polypharmacy's role in symptom presentation, vestibular testing results, and therapeutic strategies.

来源:Ear Hear,查看原文。版权归原作者所有。

引用

  1. Jeong SS, Chen T, Timor TA, et al. Prevalence of Polypharmacy in Patients With Vestibular and Balance Complaints. Ear Hear. 2022. PMID: 36377041. doi:10.1097/AUD.0000000000001292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。